Stock data
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE) reported net income of -US$12.60M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$13.23M | -US$12.60M | — |
| 2024 | — | — | -US$14.32M | -US$12.96M | — |
| 2023 | — | — | -US$15.47M | -US$14.29M | — |
| 2022 | — | — | -US$113.39M | -US$112.66M | — |
| 2021 | — | — | -US$37.45M | -US$37.13M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$3.59M | — |
| 2026-03-31 | — | -US$3.29M | — |
| 2025-12-31 | — | -US$2.46M | — |
| 2025-09-30 | — | -US$2.97M | — |
| 2025-06-30 | — | -US$3.24M | — |
| 2025-03-31 | — | -US$3.93M | — |
| 2024-12-31 | — | -US$2.89M | — |
| 2024-09-30 | — | -US$3.78M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.